S Smathers1, K Wallner, T Korssjoen
1Department of Radiation Oncology, University of Washington, Seattle, USA.
Patients receiving iodine-125 (I-125) or palladium-103 (Pd-103) prostate brachytherapy pose minimal radiation risk to the public. Exposure levels are well within regulatory limits, ensuring patient and public safety post-procedure.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: